Freezing tumors may boost immunotherapy in advanced lung cancer: new trial
NCT ID NCT04339218
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether freezing a tumor (cryoablation) plus standard immunotherapy and chemotherapy helps people with advanced lung cancer live longer. About 214 participants will be randomly assigned to receive either the standard drug combination alone or with the freezing treatment. The main goal is to see if adding cryoablation improves survival at one year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRYOTHERAPY EFFECT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Bergonié
RECRUITINGBordeaux, Gironde, 33076, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI be a Pathologist's second opinion?
- Blood tests could unlock early clues for three major lung diseases
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
- Why some Never-Smokers get lung cancer: a new study investigates
- Cold spray could take the sting out of blood gas tests
- Could an asthma drug help fight lung cancer? early trial investigates